Drawing for AAVANTIBIO ADVANCING THERAPY FOR FRIEDREICH'S ATAXIA

USPTO serial 88359968

AAVANTIBIO ADVANCING THERAPY FOR FRIEDREICH'S ATAXIA

Reviewed by CopyMark Law Group

Status 606
Filing date
Status date
Registration date
—
Examiner
DUBRAY, KATHERINE M
Law office
INTENT TO USE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with AAVANTIBIO ADVANCING THERAPY FOR FRIEDREICH'S ATAXIA?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Jonathan M. Gelchinsky

Jonathan M. Gelchinsky Pierce Atwood LLP254 Commercial StreetPortland, ME 04101UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Biological treatments, namely, biological preparations, for use for clinical, medicinal and the therapeutic treatment of Friedreich's Ataxia and genetic disorders; biological preparations for the treatment of Friedreich's Ataxia and genetic disorders; Biospecific reagents for medical use, for use in immunotherapy for the treatment of Friedreich's Ataxia and genetic disorders; Biological preparations for use in immunotherapy for the treatment of Friedreich's Ataxia and genetic disorders; Biological preparations, namely, biological drugs in the nature of gene therapy products for use for clinical, medicinal and therapeutic treatment of Friedreich's Ataxia; biological preparations, namely, biological drugs in the nature of gene therapy products for treatment of genetic diseases and Friedreich's Ataxia; biological preparations, namely, biological drugs in the nature of gene therapy products for use in treating Friedreich's Ataxia and autoimmunity disorders and diseases; biological preparations, namely, gene therapy products in the nature of therapeutic pharmaceuticals for the treatment of Friedreich's Ataxia, autoimmune, immune system diseases and disorders; pharmaceutical preparations for human use for the treatment of Friedreich's Ataxia; Therapeutic pharmaceutical preparations and medical diagnostic agents and preparations for use in therapies for Friedreich's Ataxia and autoimmunity, all of the foregoing for medical use; Therapeutic pharmaceutical preparations and diagnostic agents, preparations and substances for medical purposes for targeting application to immunotherapies and therapeutic and diagnostic agentsACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB6): The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.

DateCodeEventWhat it means
May 8, 2023MAB6ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
May 8, 2023ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Feb 22, 2023DOCKASSIGNED TO EXAMINER—
Oct 4, 2022EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Oct 3, 2022EX5GSOU EXTENSION 5 GRANTED—
Sep 27, 2022EXT5SOU EXTENSION 5 FILED—
Sep 27, 2022EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Apr 7, 2022EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Apr 5, 2022EX4GSOU EXTENSION 4 GRANTED—
Apr 5, 2022EXT4SOU EXTENSION 4 FILED—
Apr 5, 2022EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Sep 18, 2021EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Sep 16, 2021EX3GSOU EXTENSION 3 GRANTED—
Sep 16, 2021EXT3SOU EXTENSION 3 FILED—
Sep 16, 2021EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Sep 7, 2021CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
Sep 7, 2021TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Sep 7, 2021ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Sep 7, 2021REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Sep 7, 2021COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
Apr 21, 2021EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Apr 20, 2021EX2GSOU EXTENSION 2 GRANTED—
Apr 20, 2021AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
Apr 6, 2021EXT2SOU EXTENSION 2 FILED—
Apr 6, 2021EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Oct 8, 2020EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Oct 6, 2020EX1GSOU EXTENSION 1 GRANTED—
Oct 6, 2020EXT1SOU EXTENSION 1 FILED—
Oct 6, 2020EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Apr 7, 2020NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Feb 11, 2020NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Feb 11, 2020PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jan 22, 2020NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Jan 2, 2020CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Dec 31, 2019XAECEXAMINER'S AMENDMENT ENTERED—
Dec 31, 2019GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Dec 31, 2019GNEAEXAMINERS AMENDMENT E-MAILED—
Dec 31, 2019CNEAEXAMINERS AMENDMENT -WRITTEN—
Dec 13, 2019TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Dec 12, 2019CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Dec 12, 2019TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Oct 2, 2019ASGNAUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP—
Jun 12, 2019GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 12, 2019GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 12, 2019CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 6, 2019DOCKASSIGNED TO EXAMINER—
Apr 15, 2019NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Mar 30, 2019NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance